A practical approach for assessing chemosensitivity in colorectal cancer cell lines by comparative analysis of cell viability and thymidylate synthase mRNA expression

Hyun Yong Hwang

Department of Laboratory Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea

**Purpose:** The purpose of this study is to suggest a probable problem in chemosensitivity tests performed in practice and to speculate on practicable measures for more accurate chemosensitivity evaluation. **Methods:** Three colorectal cancer cells (RSC, RRC1, and RRC2) were treated with 5-fluorouracil (5-FU). Inhibition percentage (%inhibition) of cancer cells and relative quantitation of thymidylate synthase (TS) mRNA were measured on day 2, day 5 after replacement of 70% media on day 2, day 7, and day 3 after replacement of all media on day 7. Doses that produced 50% inhibition (Dm) were calculated to evaluate drug effect. Relative quantitation of TS mRNA and correlations between TS mRNA levels and 5-FU concentrations were analyzed. **Results:** RRC1 was more resistant than RRC2 on day 7, but Dm value of RRC2 increased three days after replacement of media from 12.3 to 18.1. Mean TS mRNA levels of RSC on D2 and D7 were significantly lower than those of RRC1 and RRC2, respectively (P = 0.004, P = 0.004 on D2; P = 0.010, P = 0.006 on D7). TS mRNA levels in RRC1 were significantly reversely correlated with 5-FU concentrations on day 2 (correlation coefficient = −0.867, P = 0.015). On the other hand, correlations were not significant in RRC2 (r = 0.067). **Conclusion:** Evaluating %inhibition of cancer cells at one point in chemosensitivity tests seems to be inadequate in determining chemotherapeutic regimens. Multilateral approaches, such as trials evaluating cancer cell survival before and after media replacement and correlations between TS mRNA levels and 5-FU concentrations, needs to be implemented for the practical application of chemosensitivity tests.

**Key Words:** Drug effects, 5-fluorouracil, Thymidylate synthase

**INTRODUCTION**

When chemosensitivity testing is performed for chemotherapy in patients, the interpretation of it is usually done on day 2 to 7 after test [1-5]. This is just considering inhibition percentage (%inhibition) of cancer cells at one point in the lifetime of the cancer cells; however, the inhibition rates of cancer cells in vivo may differ depending on the characteristics of the cancer cell, which might cause some unexpected results in practice. If unexpected behav-
iors relating to genetic characteristics are observed in cancer cells after chemosensitivity tests have been completed, it might be dangerous to treat patients according to the results of the test. Here, the author intends to suggest a likely problem in chemosensitivity testing performed in practice and speculates on practicable measures for more accurate chemosensitivity evaluation.

**METHODS**

**Cancer cell and chemical**

Three kinds of cancer cells (RSC, RRC1, and RRC2) were derived from SNU-C2A and SNU-C1 colorectal cancer cell lines purchased from the Korean cell line bank. The cancer cells were cultured in Dulbecco's Modified Eagle's Medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (Invitrogen), 50,000 U/L penicillin (Invitrogen), 80 μM streptomycin (Invitrogen), and 0.25 μg amphotericin B (Invitrogen) in a humidified incubator (Sanyo, Gunma, Japan) at 37°C with an atmosphere of 10% CO2. 5-fluorouracil (5-FU) was used as a cancer drug. 50 μg/mL was used as 100% treatment dose of 5-FU.

**Culture and treatment**

Cancer cells were cultured in 96-well plates for chemosensitivity and 6-well plates for mRNA quantitation. Cancer cells were treated with serially diluted 5-FU from 0 (no drug) to 200% treatment dose. Each cancer cell line was plated in a 96-well plate at a density of $5 \times 10^5$ cells/well and in a 6-well plate at a density of $8 \times 10^4$ cells/well, respectively. Negative control (no cell) was also included in each evaluation plate. Inhibition percentage of cancer cell and relative quantitation of thymidylate synthase (TS) mRNA were measured in each 96-well plate and 6-well plate on day 2 (D2), day 5 after 70% media replacement on day 2 (D2 + 5), day 7 (D7), and day 3 after 100% media replacement on day 7 (D7 + 3), respectively. Here, media replacement was intended to induce regrowth of cancer cells.

**Chemosensitivity evaluation**

The effect of the drug on cell viability was tested using a CellTiter 96 Aqueous non-radioactive cell proliferation assay kit (Promega Co., Madison, WI, USA). After incubating the test plate with reagents of the assay kit for 2 hours at 37°C in a humidified 5% CO2 atmosphere, absorbance at 490 nm was measured using a microplate reader. Tests were repeated three times, and the means of the test results were used for analyses. Inhibition percentage of cancer cell line was calculated using the following equation:

$$\frac{T}{C} = \frac{\text{Absorbance of cultured cancer cell treated with 5-FU}}{\text{Absorbance of cultured cancer cell not treated with 5-FU}}$$

$$\%\text{inhibition of cancer cell} = (1 - \frac{T}{C}) \times 100$$

**Fig. 1.** Amplification curve of realtime quantitative polymerase chain reaction (PCR) for thymidylate synthase (TS) mRNA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). FAM dye and JOE dye were used for TS mRNA and GAPDH, respectively. One cycle of reverse transcription (stage 1, 42°C 5 minutes; stage 2, 95°C 10 seconds) and 40 cycles of PCR reaction (stage 3, 95°C 5 seconds; 60°C 30 seconds) were performed for real-time quantitative PCR. Blue lines and yellow lines indicate TS mRNA and GAPDH, respectively. All tested extracted RNAs were drawn in the figure together.
Median-effect dose (Dm), the dose that produces 50% effect, was calculated with CalcuSyn (Biosoft, Cambridge, UK).

Relative quantitation of TS mRNA

RNA was extracted from cancer cell using the Absolutely RNA Microprep kit (Stratagene, La Jolla, CA, USA). Quantitative real-time polymerase chain reaction (PCR) was performed with the One Step PrimeScript RT-PCR kit (Takara Bio Inc., Shiga, Japan); transcription of cDNA and quantitation of TS mRNA with TaqMan TS mRNA gene expression assay kit (Applied Biosystems, Foster City, CA, USA) were performed in the ABI prism 7700 (Applied Biosystems). TaqMan glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Applied Biosystems) was used as an internal control. Relative quantitation of TS mRNA was calculated with TS mRNA and GAPDH (Fig. 1).

Statistical analysis

TS mRNA levels in each cancer cell on four evaluation days were compared by Mann-Whitney U test. To analyze the difference of TS mRNA quantitation according to the change of 5-FU concentration on each evaluation day, the correlation between TS mRNA level and 5-FU concentration was evaluated with Kendall’s tau-b. Statistical significance was established at the P < 0.05 level for each analysis.

RESULTS

Chemosensitivity evaluation

RSC was the most sensitive on all evaluation days (Table 1, Fig. 2). RRC1 was the most resistant against 5-FU on D2 and D7. Dm values of RRC1 were 6.9 times and 4.6 times higher than RSC and RRC2 on D2, respectively, and those of RRC1 on D7 were 9 times and 1.7 times higher than RSC and RRC2 on D7, respectively. RRC2 was the most resistant on D2 + 5 and D7 + 3. Dm values of RRC2 were 3.1 times

---

**Table 1.** Dm values and mean values of TS mRNA in each cancer cell

| Evaluation day | Cell | Dm value | TS mRNA mean (SD) |
|---------------|------|----------|-------------------|
| D2            | RSC  | 60.6     | 0.65 (0.20)       |
|               | RRC1 | 415.7    | 2.60 (0.71)       |
|               | RRC2 | 90.0     | 2.45 (0.24)       |
| D2 + 5        | RSC  | 5.8      | 1.36 (1.55)       |
|               | RRC1 | 17.1     | 2.87 (0.20)       |
|               | RRC2 | 18.3     | 2.92 (0.24)       |
| D7            | RSC  | 5.8      | 2.92 (0.24)       |
|               | RRC1 | 17.1     | 2.87 (0.20)       |
|               | RRC2 | 18.3     | 2.92 (0.24)       |
| D7 + 3        | RSC  | 1.8      | 5.62 (7.24)       |
|               | RRC1 | 7.0      | 2.98 (0.61)       |
|               | RRC2 | 18.1     | 2.97 (0.22)       |

Dm, median-effect dose; TS, thymidylate synthase. D2, day 2; D2 + 5, day 5 after 70% media replacement on day 2; D7, day 7; D7 + 3, day 3 after 100% media replacement on day 7.

---

**Fig. 2.** Dose-effect curve on each evaluation day. Shown are dose-effect curve on D2 and D2 + 5 (A) and D7 and D7 + 3 (B) in each cancer cell line. D2, day 2; D2 + 5, day 5 after 70% media replacement on day 2; D7, day 7; D7 + 3, day 3 after 100% media replacement on day 7.
Table 2. Change of Dm values after media replacement

| Change of Dm value after media replacement (%) | D2 vs. D2+5 | D7 vs. D7+3 |
|-----------------------------------------------|-------------|-------------|
| RSC                                           | 9.6 ↓ a)   | 78.3 ↓     |
| RRC1                                          | 4.1 ↓      | 33.8 ↓     |
| RRC2                                          | 20.3 ↓     | 147.2 ↑ b) |

Dm, median-effect dose; D2, day 2; D2+5, day 5 after 70% media replacement on day 2; D7, day 7; D7+3, day 3 after 100% media replacement on day 7.

a) Decrease. b) Increase.

Relative quantitation of TS mRNA

Mean TS mRNA levels in RSC in tested 5-FU concentrations were lower than those of RRC1 and RRC2 on D2, D2+5, and D7; however, TS mRNA value of RSC was higher than those of RRC1 and RRC2 on D7 (Table 1).

Mean TS mRNA levels of RSC on D2 and D7 were significantly lower than those of RRC1 and RRC2, respectively (P = 0.004, P = 0.004 on D2; P = 0.010, P = 0.006 on D7).

Fig. 3. Relative quantitation of thymidylate synthase (TS) mRNA in serially diluted 5-fluorouracil (5-FU) concentrations. Correlations between TS mRNA levels and 5-FU concentrations were evaluated with Kendall’s tau-b on D2 (A), D2+5 (B), D7 (C), and D7+3 (D). D2, day 2; D2+5, day 5 after 70% media replacement on day 2; D7, day 7; D7+3, day 3 after 100% media replacement on day 7.
Correlation between TS mRNA values and 5-FU concentrations

TS mRNA levels in RRC1 were significantly reversely correlated with 5-FU concentrations on D2 (correlation coefficient, r = -0.867). On the other hand, correlations were not significant in RRC2 (r = 0.067) (Fig. 3). Those correlations in RSC were not as strong on D2 (r = 0.600) but significantly strong on D7 and D7+3 (r = 0.867, r = 1.000, respectively).

DISCUSSION

In Table 1 and Fig. 2, chemosensitivity against 5-FU on D7 indicated that RSC was the most sensitive and RRC1 was the most resistant among tested cancer cells. RRC1 is more resistant to 5-FU than RRC2 on D7, but %inhibition in RRC1 and RRC2 showed some changes on D7+3. Dm value increased from 12.3 to 18.1 in RRC2 while decreasing continuously in RRC1 (Tables 1, 2). If the chemosensitivity is decided on D7, RRC1 is definitely the most resistant among tested cancer cells in this study. However, the most resistant to 5-FU is RRC2 on D7+3. If this happens in patients, it would be difficult to decide whether or not to accept the results of chemosensitivity on D7. This also raises the question of whether the chemosensitivity test measuring %inhibition of cancer cells at one point of their lifetime could completely guarantee the destination of cancer cells after chemotherapy in vitro.

Here, the author evaluated %inhibition of cancer cells before and after media replacement intended to help re-growth of cancer cells after chemotherapy. This was also an attempt to make a cultural environment closer in similarity to in vivo status, because less damaged cancer cells would normally obtain enough nutrients from the body after the direct effects of chemotherapy ended. As a result, evaluating %inhibition of cancer cells before and after media replacement seemed to be helpful to better differentiate between sensitive and resistant cancer cells in this study.

When 5-FU is administered to patients, its metabolite, 5-fluoro-2’-deoxyuridine-5’-monophosphate, binds to TS involved in DNA synthesis [7-9]. Significant relations between TS levels and 5-FU sensitivity have been reported [10,11]. Although the correlation between TS mRNA and protein expression is not always significant [12], TS mRNA levels are known to be higher in the 5-FU resistant cancer group compared to the 5-FU sensitive group [13-15].

In Table 1, mean values of TS mRNA in RSC on D2 and D7 showed significantly low values compared to those in RRC1 and RRC2, respectively (P = 0.004, P = 0.004 on D2; P = 0.010, P = 0.006 on D7). On D2+5 and D7+3, relative quantitations of TS mRNA at 100 and 200% treatment dose of 5-FU in RSC were very high compared to those at other concentrations. After all, these increased levels are thought to make it difficult to differentiate between RSC and RRC1 or between RSC and RRC2 on D2+5 and D7+3.

TS levels as determined by enzyme activity assays, immunohistochemistry and mRNA expression were reported to be initially decreased by 5-FU treatment, which were followed by induction of TS [16]. When patients with colorectal cancer were given one presurgery bolus of 5-FU, TS mRNA expressions in primary cancer cells of exposed patients were higher than in those of unexposed patients [17]. These studies indicate that 5-FU exposure can affect TS mRNA expression levels in cancer cells. However, the correlations between TS mRNA levels and 5-FU concentrations are not well known.

In Fig. 3, significant correlation between TS mRNA levels in RRC1 and 5-FU concentrations were observed on D2 (correlation coefficient, r = -0.867), but such significant correlations were not found in RRC2 (r = 0.067) (Fig. 3). And those correlations in RSC were also significantly strong on D7 and D7+3 (r = 0.867, r = 1.000, respectively). Correlations between TS mRNA values and 5-FU concentrations, as well as mean values of TS mRNA in Table 1, combine to be able to differentiate among RSC, RRC1, and RRC2 in this study. Although TS enzyme activity was not measured in this study, changes in TS mRNA expression levels to 5-FU concentrations seem to affect the response of cancer cells against 5-FU treatment.

Each cancer cell has its own genetic characteristic reported to cause different responses against the same chemotherapeutic environment [18-20]. And chemotherapy itself is a very invasive procedure compared to antibiotics.
treatment in patients, which makes physicians very careful and sometimes hesitant to treat patients according to the chemosensitivity results. Therefore, various approaches to provide more accurate chemosensitivity have to be developed for practical application.

In Korea, two assay methods for chemosensitivity, histoculture drug response assay and adenosine triphosphate-based chemotherapy response assay are being used in practice [4,5]. As previously mentioned, those tests only evaluate %inhibition of cancer cell at one point after chemotherapy, which might not always predict the destination of cancer cells due to different characteristics of individual cancer cells.

Chemosensitivity tests measuring inhibition of cancer cells do not evaluate pharmacokinetic and pharmacogenetic processes significantly affecting chemosensitivity in the body. An integrated approach based on a pharmacokinetic analysis combined with dihydropyrimidine dehydrogenase genotyping and/or phenotyping has been suggested to be a safer strategy for optimizing the administration of 5-FU [21]. And a combination of germline TS polymorphisms was reported to be an independent prognostic marker in selecting colorectal cancer patients with poor prognosis [22]. However, commercially available chemosensitivity tests measuring cancer cell survival have excluded these pharmacokinetic and pharmacogenetic perspectives until now.

Although more numbers of cases showing conversion of Dm values as seen in this study are needed to make conclusive results more concrete, evaluating %inhibition of cancer cells at one point in a chemosensitivity test seems to be insufficient to determine chemotherapeutic regimens. Multilateral approaches, such as trials in this study evaluating cancer cell survival before and after media replacement and correlations between TS mRNA levels and 5-FU concentrations, need to be implemented for the practical application of chemosensitivity testing.

**CONFLICTS OF INTEREST**

No potential conflict of interest to relevant this article was reported.

**ACKNOWLEDGEMENTS**

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (KRF-2008-331-E00311).

**REFERENCES**

1. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990;82:1113-8.
2. Sevin BU, Peng ZL, Perras JP, Ganjei P, Penalver M, Aveert M. Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynekol Oncol 1988;31:191-204.
3. Kinoshita M, Kodera Y, Hibi K, Nakayama G, Inoue T, Ohashi N, et al. Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy. Anticancer Res 2007;27:851-6.
4. Huh JW, Park YA, Lee KY, Sohn SK. Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer—secondary publication. Yonsei Med J 2009;50:697-703.
5. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995;1:305-11.
6. Blumenthal RD. Chemosensitivity. Vol. 1, In vitro assays. Totowa: Humana Press; 2005.
7. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, et al. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 1999;5:883-9.
8. Langenbach RJ, Danenberg PV, Heidelberger C. Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2′-deoxyuridylate. Biochem Biophys Res Commun 1972;48:1565-71.
9. Jung H, Lee J, Lee HH, Kim SH, Hur H, Jeon HM. Gastric cancer susceptibility according to methylenetetrahydrofolate reductase and thymidylate synthase gene polymorphism. J Korean Surg Soc 2010;79:27-34.
10. Johnston PG, Drake JC, Trepel J, Allegra CJ. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 1992;52:4306-12.
11. Van Triest B, Peters GJ. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology 1999;57:179-94.
12. Grem JL, Danenberg KD, Behan K, Parr A, Young L, Danenberg PV, et al. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. Clin Cancer Res 2001;7:999-1009.

13. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-12.

14. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322-7.

15. Okumura K, Mekata E, Shiomi H, Naitoh H, Abe H, Endo Y, et al. Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer. Cancer Chemother Pharmacol 2008;61:587-94.

16. Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002;1587:194-205.

17. Mauritz R, van Groeningen CJ, Smid K, Jansen G, Pinedo HM, Peters GJ. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer. Int J Cancer 2007;120:2609-12.

18. Brennetot C, Buhard O, Jourdan F, Flejou JF, Duval A, Hamelin R. Mononucleotide repeats BAT-26 and BAT-25 accurately detect MSI-H tumors and predict tumor content: implications for population screening. Int J Cancer 2005;113:446-50.

19. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000;355:1745-50.

20. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57.

21. Bocci G, Di Paolo A, Barbara C, Masi G, Fornaro L, Loupakis F, et al. Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction. Br J Clin Pharmacol 2009;67:132-4.

22. Hitre E, Budai B, Adleff V, Czeglédi F, Horáth Z, Gyergyay F, et al. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet Genomics 2005;15:723-30.